Physician profile
David Baumgarten
NPI 1770920720
$6,454.48
in general payments reported to CMS, 2019-2025
31 companies · $1,900 in 2025
The $1,900 reported for 2025 was more than what 86% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $36.59 · 2021: $461 · 2022: $1,239 · 2023: $1,148 · 2024: $1,529 · 2025: $1,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,576.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,854.22 | 2020-2025 | Breztri, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,316.49 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $652.61 | 2021-2025 | Dupixent |
| Genzyme Corporation | $503.24 | 2021-2025 | |
| Philips North America LLC | $293.74 | 2022-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Genentech USA, INC. | $232.41 | 2019-2025 | Xolair |
| Jazz Pharmaceuticals INC. | $161.92 | 2023-2025 | Xywav |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.84 | 2021-2023 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Amgen INC. | $146.69 | 2023-2025 | Tezspire |
| Harmony Biosciences LLC | $145.71 | 2022-2025 | Wakix |
| Verona Pharma, INC. | $111.35 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $105.21 | 2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $105.06 | 2023-2025 | Aralast |
| Mylan Specialty L.P. | $96.38 | 2020-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $94.67 | 2019-2024 | Uptravi, Opsumit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $93.64 | 2025 | |
| Abiomed | $50.58 | 2024 | Impella |
| Novartis Pharmaceuticals Corporation | $40.15 | 2022-2023 | |
| Abbvie INC. | $36.17 | 2025 | |
| Grifols USA, LLC | $35.84 | 2022-2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $35.76 | 2024 | |
| Axsome Therapeutics, INC. | $34.83 | 2025 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $27.53 | 2022 | |
| Insmed, INC. | $27.34 | 2021-2022 | |
| Lilly USA, LLC | $16.28 | 2025 | Zepbound |
| Pulmonx Corporation | $16.20 | 2022 | |
| Allergan, INC. | $15.00 | 2019 | |
| Merck Sharp & Dohme LLC | $14.28 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.19 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $14.04 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Baumgarten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.